RxDoctor Payments Data

Melissa Gunther, PA

Physician Assistant · Salisbury, MDNPI 1629342910

Payments from drug & device makers

$4,782in general payments, 2019–2025

Across 150 payments — averaging $31.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Novo Nordisk$395
  • AbbVie$279
  • Pfizer$227
  • Lilly USA, LLC$205
  • Ferring Pharmaceuticals Inc.$121
  • plus $979 from 20 others

What the payments were for

  • Speaking & faculty fees$1,90140%
  • Travel & lodging$30%
  • Food & beverage$2,85460%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,782 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$89,313
Medicare patients
368
Services billed
1,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$112,620
JardianceEmpagliflozin89$108,193
Repatha SureclickEvolocumab49$63,205
EliquisApixaban57$61,236
MounjaroTirzepatide42$49,563
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$34,092
TrulicityDulaglutide13$23,903
GemtesaVibegron19$19,963
EntrestoSacubitril/Valsartan19$18,189
LinzessLinaclotide17$17,331
XareltoRivaroxaban11$14,123
Rosuvastatin Calcium454$13,079
Breo ElliptaFluticasone/Vilanterol22$12,298
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$11,753
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$11,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$54$127,423118 claims
Novo NordiskOzempic$395$112,62082 claims
Lilly USA, LLCMounjaro, Trulicity$205$73,46655 claims
PfizerEliquis$227$61,23657 claims
AbbVieLinzess, Ubrelvy, Synthroid$279$30,40972 claims
Sumitomo Pharma America, Inc.Gemtesa$44$19,96319 claims
AstraZenecaBreztri Aerosphere, Farxiga$111$19,28724 claims
NovartisEntresto$92$18,18919 claims
Johnson & JohnsonXarelto$99$14,12311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →